Perception beyond Tomorrow
Performance-focused co-investments aligned with stakeholders' Interests
Our Edge
“For a successful technology, reality must take precedence over public relations, for Nature cannot be fooled .” – Richard Feynman
Third Eye Development invests directly in early-stage scientific breakthroughs focusing on disruptive and transformational technologies. Third Eye's approach also prioritizes alignment with our stakeholders, emphasizing investment performance and risk-sharing, in contrast to the established private equity/venture capital business models.
DIRECT INVESTMENTS
BioTrip
BioTrip is developing a set of novel, proprietary delivery platforms that aim to harness the full potential of the immune system. Despite recent successes of RNA-based therapies and vaccines, these modalities have seen limited success in autoimmunity and oncology because current delivery modalities target a very limited set of tissues and cell types. BioTrip's platforms have the potential to address this limitation, thereby opening up entirely new fields of therapeutics and vaccines.
Reflexion Pharmaceuticals
Protein biologics, including antibodies and peptides, have become the largest selling class of therapeutics despite the fact that they can only be administered intravenously or by injection. Reflexion, as the name suggests, uses mirror image amino acids to create fully functional proteins with the unique benefits of being able to slip under the radar of the immune system and being resistant to enzymatic degradation. These features have the potential to open up new routes of administration to protein therapeutics (e.g. oral and inhalation) and to improve the performance of proteins administered by conventional routes (e.g. improved dosing and therapeutic index).